Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Net Margin (2016 - 2025)

Agios Pharmaceuticals' Net Margin history spans 12 years, with the latest figure at 541.09% for Q4 2025.

  • For Q4 2025, Net Margin rose 35847.0% year-over-year to 541.09%; the TTM value through Dec 2025 reached 767.3%, down 260442.0%, while the annual FY2025 figure was 764.01%, 260994.0% down from the prior year.
  • Net Margin reached 541.09% in Q4 2025 per AGIO's latest filing, up from 803.05% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 10574.69% in Q3 2024 to a low of 1471.24% in Q1 2023.
  • Average Net Margin over 3 years is 90.77%, with a median of 1026.7% recorded in 2025.
  • Peak YoY movement for Net Margin: soared 1180896bps in 2024, then plummeted -1137774bps in 2025.
  • A 3-year view of Net Margin shows it stood at 1350.7% in 2023, then skyrocketed by 33bps to 899.56% in 2024, then skyrocketed by 40bps to 541.09% in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Net Margin are 541.09% (Q4 2025), 803.05% (Q3 2025), and 903.6% (Q2 2025).